CoChat

Metabolic syndrome and cardiovascular disease following hematopoietic cell transplantation: screening and preventive practice recommendations from CIBMTR and EBMT

Open access
DeFilipp, Z, Duarte, R F, Snowden, J A, Majhail, N S, Greenfield, D M, Miranda, J L, Arat, M, Baker, K S, Burns, L J, Duncan, C N, Gilleece, M, Hale, G A, Hamadani, M, Hamilton, B K, Hogan, W J, Hsu, J W, Inamoto, Y, Kamble, R T, Lupo-Stanghellini, M T, Malone, A K, McCarthy, P, Mohty, M, Norkin, M, Paplham, P, Ramanathan, M, Richart, J M, Salooja, N, Schouten, H C, Schoemans, H, Seber, A, Steinberg, A, Wirk, B M, Wood, W A, Battiwalla, M, Flowers, M E D, Savani, B N, Shaw, B E, on behalf of the CIBMTR Late Effects and Quality of Life Working Committee and the EBMT Complications and Quality of Life Working Party · 2017 · Bone Marrow Transplantation
Cited by 84

The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.

Abstract

Metabolic syndrome (MetS) is a constellation of cardiovascular risk factors that increases the risk of cardiovascular disease, diabetes mellitus and all cause mortality. Long-term survivors of hematopoietic cell transplantation (HCT) have a substantial risk of developing MetS and cardiovascular disease, with the estimated prevalence of MetS being 31–49% among HCT recipients. Although MetS has not yet been proven to impact cardiovascular risk after HCT, an understanding of the incidence and risk factors for MetS in HCT recipients can provide the foundation to evaluate screening guidelines and develop interventions that may mitigate cardiovascular-related mortality. A working group was established through the Center for International Blood and Marrow Transplant Research and the European Group for Blood and Marrow Transplantation with the goal of reviewing literature and recommend practices appropriate to HCT recipients. Here we deliver consensus recommendations to help clinicians provide screening and preventive care for MetS and cardiovascular disease among HCT recipients. All HCT survivors should be advised of the risks of MetS and encouraged to undergo recommended screening based on their predisposition and ongoing risk factors.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/bmt.2016.203

Cites

14 of 14 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

1 retracted

Show all 14 references

Cited by

See all 84

Metadata

Authors
DeFilipp, Z., Duarte, R. F., Snowden, J. A., Majhail, N. S., Greenfield, D. M., Miranda, J. L., Arat, M., Baker, K. S., Burns, L. J., Duncan, C. N., Gilleece, M., Hale, G. A., Hamadani, M., Hamilton, B. K., Hogan, W. J., Hsu, J. W., Inamoto, Y., Kamble, R. T., Lupo-Stanghellini, M. T., Malone, A. K., McCarthy, P., Mohty, M., Norkin, M., Paplham, P., Ramanathan, M., Richart, J. M., Salooja, N., Schouten, H. C., Schoemans, H., Seber, A., Steinberg, A., Wirk, B. M., Wood, W. A., Battiwalla, M., Flowers, M. E. D., Savani, B. N., Shaw, B. E., & on behalf of the CIBMTR Late Effects and Quality of Life Working Committee and the EBMT Complications and Quality of Life Working Party
Venue
Bone Marrow Transplantation
Published
2016-08-22
Volume
52
Issue
2
Pages
173-182
ISSN
  • 0268-3369 (ISSN-L)
  • 1476-5365
OpenAlex
W2409486903
Cited by
84
References
14
FWCI
4.74
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Metabolic syndrome and cardiovascular disease following hematopoietic cell transplantation: screening and preventive practice recommendations from CIBMTR and EBMT. https://app.cochat.ai/papers/10.1038/bmt.2016.203
The paper
DeFilipp, Z., Duarte, R. F., Snowden, J. A., Majhail, N. S., Greenfield, D. M., Miranda, J. L., Arat, M., Baker, K. S., Burns, L. J., Duncan, C. N., Gilleece, M., Hale, G. A., Hamadani, M., Hamilton, B. K., Hogan, W. J., Hsu, J. W., Inamoto, Y., Kamble, R. T., Lupo-Stanghellini, M. T., . . . on behalf of the CIBMTR Late Effects and Quality of Life Working Committee and the EBMT Complications and Quality of Life Working Party. (2017). Metabolic syndrome and cardiovascular disease following hematopoietic cell transplantation: screening and preventive practice recommendations from CIBMTR and EBMT. Bone Marrow Transplantation. https://doi.org/10.1038/bmt.2016.203

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.